Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: what goes down for five (5) sector moves last week, needs some back-fill

September 26, 2022 7:48am

However, it’s the last week of September which has been ugly for investors, could October be worse; also, Q3 closes

Indications: 3 Negative and 4 Positive Indications with 1 Pump/Promote (BSTG – the usual suspect)

The cell and gene therapy sector shows more signs of downside movement alternating to continued weakness.

No tunnel vision here, this analyst/journalist gets into the weeds of daily share pricing and root causes

8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

Dow futures are DOWN -0.59% or (-178 points), S&P futures are DOWN -0.68% (-25 points) and NASDAQ futures are DOWN -0.55% (-62 points) early in the pre-open – so far,

U.S. equity futures fell on Monday,

European markets were falling,

Asia-Pacific markets also drop as negative sentiment infects global sentiment

Henry’omics:

On Friday, stocks ended a brutal week with the Dow finding a new intraday low for the year and while the S&P 500 broke below its June closing low with the Nasdaq also diving.

The indexes jumped to their fifth (5th) decline in the last six (6) weeks and on track to close out the week with losses. The Dow has given up about -4% this week, while both the S&P -465% and Nasdaq -5.07%.

The Dow closed DOWN -486.27 points (-1.62%) the S&P closed DOWN -64.76 points (-1.72%) while the Nasdaq closed DOWN 198.88 points (-1.80%)

RegMed Investors’ (RMi) closing bell: “a crash and burn in a brutal week. A losing and volatile week within my cell and gene therapy sector coverage list (32 down and 3 ups of 35).” … https://www.regmedinvestors.com/articles/12618

Ebb and flow:

Q3/22 – September – 1 holiday, 7 positive and 9 negative closes

• August – 1 neutral, 11 positive and 11 negative closes

• July - 1 holiday, 10 negative and 10 positive closes

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Negative Indication:

BioLife Solutions (BLFS -$0.08 to $22.23 with a negative -$0.58 or -2.61% pre-open indication,

CRISPR Therapeutics (CRSP -$1.74 to $63.16 after Thursday’s -$1.75, Wednesday’s -$3.48, Tuesday’s +$1.31 and Monday’s -$1.71 with a negative -$0.47 or -0.74% pre-open indication,

Intellia Therapeutics (NTLA -$3.16 to $53.92 after Thursday’s -$2.39, Wednesday’s -$3.06, Tuesday’s -$0.94 and last Monday’s -$2.24 with a negative -$0.43 or -0.80% pre-open indication,

Positive Indications:

Agenus (AGEN) closed down -$0.11 to $2.13 with a positive +$0.05 or +2.35% pre-open indication,

Alnylam Pharmaceuticals (ALNY -$1.93 to $200.78 after Thursday’s -$3.68, Wednesday’s -$5.52, Tuesday’s -$3.99 and Monday’s +$3.00 with a positive +$0.22 or +0.11% pre-open indication,

uniQure NV (QURE) closed down -$0.29 to $17.30 with a positive +$0.81 or +$4.68% pre-open indication,

Ultragenyx (RARE) closed down -$1.64 to $41.50 with a positive +$2.58 or +6.22% pre-open indication,

Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed -$1.39 on Friday with 2,051 shares traded after Thursday’s FLAT again with 1,844 shares traded on Thursday after Wednesday’s FLAT with 3,196 shares traded, Tuesday’s +$0.10 with 9,718 shares traded, <3-month average = 2,079>,

Questions need to be answered and they NEVER are for shareholders; as the First Amendment of the U.S. Constitution does guarantee the “freedom of speech, or of the press” … but I guess NOT to respond?

How many non-citizens of Chinese nationality are employed at BSTG – 3 managers/directors of 5 and 3 of 5 board directors?
Who, WHAT and WHERE are pumping and promoting the “spikes” in volume and share price … coming from?
What is DST Capital? Is DST Capital really managed by Mrs. bin Zhao of Weston, Mass and Hong Yu, president of BSTG? Is LIU Dong-hai chairman of D. Phone, one of the largest smartphone retailers in China and Dixintong Technology group; the ultimate funder of DST Capital?
Are Chinese communist bureaucrats from Beijing, China directing the company’s activities with BSTG being their corporate “concubine”?

The BOTTOM LINE: after a tough week, some upside is due for SOME cell and gene therapy sector equities.

Especially with another quarter (Q3) about to close … and then back to earnings season – that’s LPS (loss-per-share) period!

I try to keep it simple … and short as I love my coverage list – yet, the truth will set investors free from electronic and algorithm control!

As I continually write, “The real question that should be asked is how many companies are at the end of sentiments … leash? Start by looking at cell and gene therapy companies trading below cash!”

When it comes time to invest or even hold onto an investment; I’d say … focus on what percentage ownership of stock … NOT options CEOs and management teams own versus their salary and bonus.

As I have written, “I devote a lot of time to the direction of the sector to reckon the geography of my coverage group.”

That doesn't mean you should flee entirely to cash, but investors make sure gains don't evaporate thus … be quick to drop losing positions.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.